

Target Name	$\alpha 1$ -Adrenoceptor
Target TTD ID	TTDS00027

Target Species	Human
Chemical Type	3-Arylpiperazinylalkylpyrrolo[3,2-d]pyrimidine-2,4-dione derivatives
Mode of Action	Ligand
QSAR Model 1	$\text{Aff} = 21.0309 + 0.715137 \text{ HOMO} - 1.53546 \text{ S}_{\text{ssCH2}} + 0.089448 \text{ MR} - 0.00095 \text{ PMI-mag}$ $r^2 = 0.920222, \text{ CV } r^2 = 0.734, \text{ LOF} = 0.200777$
QSAR Model 2	$\text{Aff} = 30.9349 - 1.42254 \text{ S}_{\text{ssCH2}} - 0.00085 \text{ PMI-mag} + 0.978227 \text{ HOMO}$ $r^2 = 0.843812, \text{ LOF} = 0.221106$
QSAR Model 3	$\text{Aff} = 14.9317 - 1.28305 \text{ S}_{\text{ssCH2}} - 0.001135 \text{ PMI-mag} + 0.590941 \text{ S}_{\text{dO}} + 0.88154 \text{ HOMO}$ $r^2 = 0.881520, \text{ LOF} = 0.298178$
QSAR Model 4	$\text{Aff} = -1.42385 + 0.218582 \text{ MR} - 0.000713 \text{ PMI-mag} - 1.41618 \text{ S}_{\text{ssCH2}} + 13.7639 \text{ Jurs-RPCG}$ $r^2 = 0.881415, \text{ LOF} = 0.298444$
QSAR Model 5	$\text{Aff} = 35.7893 - 0.001058 \text{ PMI-mag} + 1.20452 \text{ HOMO} - 1.71175 \text{ S}_{\text{ssCH2}} + 0.430969 \text{ Jurs-RPCS}$ $r^2 = 0.877877, \text{ LOF} = 0.307347$
QSAR Model 6	$\text{Aff} = 29.5356 - 0.033243 \text{ S}_{\text{sCl}} - 1.4278 \text{ S}_{\text{ssCH2}} - 0.000758 \text{ PMI-mag} + 0.880362 \text{ HOMO}$ $r^2 = 0.870094, \text{ LOF} = 0.326934$
QSAR Model 7	$\text{Aff} = 18.8665 + 1.10796 \text{ Jurs-RNCS} - 1.43661 \text{ S}_{\text{ssCH2}} + 0.093934 \text{ MR} - 0.000938 \text{ PMI-mag}$ $+ 0.664025 \text{ HOMO}$ $r^2 = 0.941940, \text{ LOF} = 0.328768$
QSAR	$\text{Aff} = 30.219 - 0.000863 \text{ PMI-mag} + 0.938424 \text{ HOMO} - 1.40417 \text{ S}_{\text{ssCH2}} + 0.037602 \text{ S}_{\text{ssO}}$

<b>Model 8</b>	$r^2 = 0.869239$ , LOF = 0.329087
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>MR, Thermodynamic Molar refractivity; Density, Spatial Molecular density; PMI-mag, Spatial Principal moment of inertia; Dipole-mag, Electronic Dipole moment; HOMO, Electronic Highest occupied molecular orbital energy; LUMO, Electronic Lowest unoccupied molecular orbital energy; Sr, Electronic Superdelocalizability; Jurs-RPCG, Spatial Relative positive charge; Jurs-RNCG, Spatial Relative negative charge; Jurs-RPCS, Spatial Relative positive charge surface area; Jurs-RNCS, Spatial Relative negative charge surface area; Jurs-RPSA, Spatial Relative polar surface area; S_sCH3, Electrotopological Sum for a methyl group; S_ssCH2, Electrotopological Sum for a methylene group; S_dssC, Electrotopological Sum for a carbon atom with a double bond and two single bonds (i.e., a carbonyl carbon); S_aasC, Electrotopological Sum for a carbon atom with a single bond and two aromatic bonds (i.e., a carbon of the pyrrole ring); S_ssNH, Electrotopological Sum for a nitrogen atom linked to a hydrogen and involved in two additional single bonds;(i.e., the NH group of the pyrimidinedione system); S_aaNH, Electrotopological Sum for a nitrogen atom linked to a hydrogen and involved in two additional aromatic bonds (i.e., the NH group of the pyrrole ring); S_dO, Electrotopological Sum for an oxygen atom bound through a double bond (i.e., a carbonyl oxygen); S_ssO, Electrotopological Sum for an oxygen atom bound through two single bonds (i.e., the oxygen of a methoxy group); S_sCl, Electrotopological Sum for a chlorine atom; Aff represents <math>\log(1/K_i)</math> where <math>K_i</math> is the affinity of compounds toward R1-ARs, expressed in nM. <math>r^2</math>, CV <math>r^2</math>, and LOF are the correlation coefficient, the cross-validated correlation coefficient, and the lack-of-fit values, respectively.</p>
<b>Reference</b>	Synthesis of 3-Arylpiperazinylalkylpyrrolo[3,2-d]pyrimidine-2,4-dione Derivatives as Novel, Potent, and Selective $\alpha 1$ -Adrenoceptor Ligands. <i>J. Med. Chem.</i> 2005, 48, 2420-2431

<b>Target Species</b>	Human
<b>Chemical Type</b>	Arylpiperazines
<b>Mode of Action</b>	Antagonist

<b>QSAR Model 1</b>	$pK_2 = 31.556 (\pm 10.768) + 5.221 (\pm 1.707) S_{10} - 1.382 (\pm 0.238) S_{16} - 2.197 (\pm 0.832) S_{21} - 1.560 (\pm 0.367) I_1$ <p> <math>n = 32; R = 0.807; \%EV = 65.18; R_A^2 = 0.600; F(4, 27) = 12.634;</math>  <math>p &lt; 0.0000; S.E.E. = 0.646</math> </p>
<b>QSAR Model 2</b>	$pK_2 = 26.139 (8.839) + 4.719 (\pm 1.389) S_{10} - 1.689 (\pm 0.209) S_{16} - 1.705 (\pm 0.686) S_{21} - 1.649 (\pm 0.298) I_1 + 1.709 (\pm 0.440) I_2$ <p> <math>n = 32; R = 0.883; \%EV = 77.97; R_A^2 = 0.737; F(5, 26) = 18.399; p &lt; 0.0000; S.E.E. = 0.523</math> </p>
<b>QSAR Model 3</b>	$pK_2 = 26.956 (\pm 8.098) + 3.841 (\pm 1.321) S_{10} - 1.915 (\pm 0.212) S_{16} - 1.671 (\pm 0.628) S_{21} - 1.907 (\pm 0.292) I_1 + 1.871 (\pm 0.408) I_2 - 0.756 (\pm 0.308) I_3$ <p> <math>n = 32; R = 0.907; \%EV = 82.25; R_A^2 = 0.780; F(6, 25) = 19.304; p &lt; 0.0000; S.E.E. = 0.479</math> </p>
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>S10 (E-state index of atom 10).</p> <p>E-state indices of atoms 8, 16, 21—S8, S16 and S21 I1, I2, represent presence of CONHPr group at ortho position and Br at meta position of the phenyl ring respectively.</p> <p>n is number of data points, R is correlation coefficient, %EV, <math>R_A^2</math>, F, p, S.E.E. are percentage of explained variance, adjusted <math>R^2</math>, ratio between the variances of observed and calculated activities, probability factor related to F-ratio and standard error of estimate respectively.</p> <p>DC is the deleted compound behaves as outliers may act through a different mechanism of action. The statistical quality of eq 3 was found to be of significant. It explains 87.30% of the variances in the activity data.</p>
<b>Reference</b>	<p>QSAR Study on the Affinity of Some Arylpiperazines towards the 5-HT1A/<math>\alpha</math>1-Adrenergic Receptor Using the E-State Index. <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 13 (2003) 2837–2842</p>

<b>Target Species</b>	Human
<b>Chemical Type</b>	Arylpiperazinylthioalkyl derivatives
<b>Mode of</b>	Binder

Action	
QSAR Model 1	$pK_i(\alpha_1) = 0.717 + 14.496(2.028)GGI9 + 1.915(0.378)GATS3e + 0.132(0.017)H - 047$ $n = 18, r = 0.942, s = 0.207, F = 36.520, Q_{LOO}^2 = 0.798,$ $Q_{I30}^2 = 0.731, FIT = 4.058,$ $LOF = 0.075, AIC = 0.068, r_{randY}^2(s.d.) = 0.366(0.154),$ $r_{Test}^2 = 0.749, R_p^2 = 0.766$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Descriptor classes and identified descriptors in modeling the <math>\alpha_1</math>-binding activity of arylpiperazinylthioalkyl derivatives.</p> <p><b>Descriptor class:</b> Identified descriptors and their average regression coefficient (incidence)</p> <p><b>CONST:</b> AMW, 0.400(1); nDB, 0.360(1); nBnz, 0.421(1); <b>TOPO:</b> AAC, 2.287(2); ZM2V, 0.008(1); PJI2, 3.427(4); IVDE, 2.973(3); IC3, 3.081(1); piPC03, 0.016(1); <b>BCUT:</b> BEHm4, 11.776(1); BELm4, 3.791(1); BEHv8, 6.231(3); <b>GALVEZ:</b> GGI6, 3.692(1); GGI8, -4.563(1); GGI9, 12.974(6); GGI10, -15.802(1); JGI1, -11.673(2);</p> <p><b>2D-AUTO:</b> ATS6m, 0.059(1); MATS3m, 42.727(3); MATS4m, 60.897(1); MATS3v, 7.851(3); MATS6v, 5.357(2); MATS1e, 2.862(1); MATS2e, 3.951(3); MATS6e, 4.000(1); MATS7e, 5.209(8); MATS6p, 5.051(2); GATS3e, 1.915(1); GATS4p, 4.962(1); GATS5p, 1.872(1); GATS6p, 4.538(2); <b>ACF:</b> C-026, 0.341(1); C-034, 0.209(2); H-047, 0.107(6); H-053, 0.291(2).</p> <p>Binding data pertaining to <math>\alpha_1</math>-adrenergic receptor.</p>
Reference	<p>A rationale for the activity profile of arylpiperazinylthioalkyls as 5-HT<sub>1A</sub>-serotonin and <math>\alpha_1</math>-adrenergic receptor ligands. <i>European Journal of Medicinal Chemistry</i> 45 (2010) 1927–1934</p>